Albumin-binding ZD2-SN38 conjugates extend half-life 100-fold in pancreatic cancer model

The wire

1. 01Researchers built Mc-ZD2-SN38 and SSC-ZD2-SN38, peptide-drug conjugates targeting extra domain B fibronectin, reporting roughly 100-fold and 15-fold longer half-life than the non-albumin-binding ZD2-SN38.
2. 02Peptide-drug conjugates are an active pipeline route for approved peptide therapeutics, and albumin binding offers a route to longer dosing intervals with lower off-target exposure.
3. 03Findings come from a BxPC-3 mouse xenograft only, with no human data and no reported path to clinical development.

From the source

Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma

Pharmaceutics · 2026 Aug 19 · Su Y, Lu Y, Yu J et al.